| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; 2 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; 3 Cancer Prevention Program, Jewish General Hospital and McGill University, Montreal, Canada; 4 Cancer Prevention Studies Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD; and 5 Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland
Requests for reprints: Rachel Stolzenberg-Solomon, NCI, NIH, Nutritional Epidemiology, 6120 Executive Boulevard, Suite 320, (EPS) Room 7039, MSC 7232, Bethesda, MD 20892-7232. Phone: (301) 594-2939; Fax: (301) 496-6829. E-mail: rs221z{at}nih.gov
To investigate whether insulin-like growth factor (IGF)-1 and IGF-binding protein-3 (IGFBP-3) are prospectively associated with exocrine pancreatic cancer, we conducted a nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort of 29,133 male Finnish smokers, aged 50–69 years. To avoid the potential influence of subclinical cancer on IGF-1 and IGFBP-3, all subjects in this study were alive without clinical evidence of cancer during their 5th year of the cohort follow-up. Four hundred randomly selected cohort controls and 93 incident pancreatic adenocarcinoma cases that occurred between their 5th follow-up year through 1997 (i.e., up to 12.7 years of follow-up) were included in this study. Concentrations of IGF-1 and IGFBP-3 were measured in serum samples obtained at baseline using ELISA. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, adjusted for confounders. Neither IGF-1, IGFBP-3, nor the IGF-1:IGFBP-3 molar ratio was significantly associated with pancreatic cancer: highest compared to lowest tertile, OR = 0.67, 95% CI 0.37–1.21, P trend = 0.17; OR = 0.70, 95% CI 0.38–1.27, P trend = 0.12; and OR = 0.85, 95% CI 0.50–1.46, P trend = 0.54, respectively. Our results do not support the hypothesis that serum IGF-1 and IGFBP-3 concentrations are associated with pancreatic cancer risk among male smokers. Further studies are necessary to evaluate these associations in other populations.
This article has been cited by other articles:
|
|
 |
|
  V. M. Chia, S. M. Quraishi, B. I. Graubard, M. V. Rubertone, R. L. Erickson, F. Z. Stanczyk, and K. A. McGlynn Insulin-like Growth Factor 1, Insulin-like Growth Factor-Binding Protein 3, and Testicular Germ-Cell Tumor Risk Am. J. Epidemiol., June 15, 2008; 167(12): 1438 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, D. S. Michaud, E. L. Giovannucci, E. S. Schernhammer, M. J. Stampfer, J. E. Manson, B. B. Cochrane, T. E. Rohan, J. Ma, M. N. Pollak, et al. Circulating Insulin-Like Growth Factor Binding Protein-1 and the Risk of Pancreatic Cancer Cancer Res., August 15, 2007; 67(16): 7923 - 7928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lonn, P. D. Inskip, M. N. Pollak, S. J. Weinstein, J. Virtamo, and D. Albanes Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 844 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ahn, S. J. Weinstein, K. Snyder, M. N. Pollak, J. Virtamo, and D. Albanes No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 2010 - 2012. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
